Surgery of colorectal liver metastasis

Slides:



Advertisements
Similar presentations
Is there a role for surgery in metastatic colorectal cancer?
Advertisements

IN THE NAME OF GOD. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy The American Journal.
Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
Staging Strategy and Treatment for Patients With HCC
Great Debates & Updates in GI Malignancies
Borderline Resectable Pancreatic Carcinoma
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Impact of the Type and Modalities of Preoperative Chemotherapy on the Outcome of Liver Resection for Colorectal Metastases R. Adam, E. Barroso, C. Laurent,
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
1 Surgical and Ablative Strategies for Treatment of Metastatic Colorectal Cancer Kim M. Olthoff, MD Associate Professor of Surgery Liver Transplantation.
Colon Cancer Basic Science 9/21/05. Colon and rectal neoplasms are characterized by: Consist of the third most common site of new cancer cases and deaths.
DEBATE: What is the Optimal Strategy for Liver Only Metastatic Colon Cancer? Michael A. Choti, MD Department of Surgery UT Southwestern Medical Center.
Joint Hospital Surgical Grand Round 16th Jan 2010 Dr James Fung Department of Surgery United Christian Hospital.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Journal Meeting 時間 : AM 07:30 日期 : 06/29/2007 地點 : 胸腔外科辦公室 報告人 : R2 許博順.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Radiofrequency Ablation of Lung Cancer
Liver Cancer ACC RNSG Risk factors 4 th most common cancer in the world Most common primary liver cancer is hepatocellular carcinoma Cirrhosis –
Surgical management of hepatic metastases from colorectal cancer Joint Hospital Surgical Grand Round Dr HH Wong Department of Surgery PYNEH.
Management of Colorectal Liver Metastasis
Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery.
Living Longer: Colon Cancer Patients Gain Time With Radiofrequency Ablation Treatment CT Sofocleous, EN Petre, M Gonen, KT Brown, RH Thornton, AM Covey,
Liver Metastases Jean-Bernard Poulard MD, MBA, FACS Mount Sinai School of Medicine Queens Hospital Center Jamaica, NY.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Dr SH Chok Department of Surgery Ruttonjee & Tang Shiu Kin Hospitals
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
A REVISIT TO MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOUR (GIST) Joint Hospital Surgical Grand Round 17 Jan 2015 Grace Liu Pamela Youde Nethersole Eastern.
Joint Hospital Grand Round 20 th May 2006 Catherine Choi United Christian Hospital.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
Guzman, Alexander Joseph Hipolito, April Lorraine
Resection For Lung Metastases M62 Coloproctology Course.
In the name of God Isfahan medical school Shahnaz Aram MD.
Mazen Hassanain. Bile duct Cancer Average age 60 years Ulcerative colitis is a common associated condition Subtypes: (1) periductal infiltrating, (2)
Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.
Nicolae Bacalbasa “Carol Davila” University Of Medicine and Pharmacy.
T4 Colon Cancer and Laparoscopic Approach Gustavo Plasencia MD FACS, FASCRS Clinical Professor of Surgery Gustavo Plasencia MD FACS, FASCRS Clinical Professor.
Pre-op Portal Vein Embolization for Major Hepatectomy SL Sin.
Potentially curative re-resection of recurrent CRC  Suture line recurrences  Isolated liver metastases  Isolated pulmonary metastases.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Laparoscopic Liver Resections David A. Kooby, MD, FACS Associate Professor of Surgery Division of Surgical Oncology Emory University School of Medicine.
Staged Hepatectomy for Colorectal Metastases to Liver Dr. Steven, Kong Ling TING Caritas Medical Centre.
Thyroid Debate (Papillary Thyroid Cancer: Extent of Thyroidectomy) 30 Aug 2007 Surgery-OMMC JGGuerra, MD HCruz, MD.
Transileocolic portal vein embolisation
Treatment should start with Chemotherapy before Surgery:
Pancreatic cancer.
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Hepatocellular carcinoma related to Hbv and Hcv
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.
Therapeutic Delay and Survival after Surgery for Cancer of the Pancreatic Head with or without Preoperative Biliary Drainage Eshuis, van der Gaag, Rauws.
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma JIN Chen, YAO Lie, LONG.
Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.
Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.
Surgery for Metastatic Brain Tumor from Breast Cancer
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Surgery As Monotherapy for Wilms’ Tumor Lisly Chéry April 15, 2010.
R3 정상완. Introduction  EGC : Tumor invasion is limited to the mucosa or submucosa, regardless of lymph node involvement.  Accumulated histopathological.
Two-Stage Hepatectomy for Unresectable Metastases :
Treatment of Colorectal Cancer Metastases to the Liver David U. Kim, MD University of Wisconsin School of Medicine and Public Health Department of Radiology.
Brain imaging prior to lung cancer resection
Liver surgery for metachronous hepatic metastases with uterine body and uterine cervix origin – a single center experience Nicolae Bacalbasa (1), Irina.
Short-term outcome of neo-adjuvant chemotherapy
SURGICAL TREATMENT OF LIVER METASTASES FROM COLORECTAL CANCER
Locally-Advanced HCC:
高雄長庚 大腸直腸外科 吳昆霖 盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全
Presentation transcript:

Surgery of colorectal liver metastasis Juozas Pundzius Surgery clinic of Kaunas university of medicine

Incidence of liver metastasis in colorectal cancer At the time of diagnosis of primary colorectal cancer: in 15-20% liver metastases are detectable In 15% udetectable liver metastases present (Synchronous disease) Sasson A.R., Sigurdson E.R. et al; Seminars in Oncology; Vol 29, No 2, 2002 After curative surgery in 20-30% developing subsequent spread to the liver; (Metachronous disease) Weinreich D Semin Oncol 29:136:144, 2002 ~ 50% of IV stage patients, liver is the only site of metastatic process; ~ 30% of patients with liver metastases are suitable for curative surgery.

Methods of treatment of liver metastasis Curative Surgical – hepatic resection; With or without adjuvant therapy; Palliative Medical – chemoterapy (systemic or regional); Surgical; Ablative techniques: RFA Ethanol injections Cryotherapy; Vesel ligation, embolization Chemoembolization Radiation

Curative possibilities of colorectal liver metastases Hepatic resection is the only form of treatment that offers a long-term survival for patients with liver metastases from colorectal cancer, with 5-year survival ranging from 25% to 39%. Tanaka K, Shimada H. et al Surgery Vol. 137:156-163, 2005

Long term results after CRC liver metastases surgery Study Year No. of patients 5-year survival (overall) Median survival (Mo) Hughes et al Scheele et al Nordlinger et al Jamison et al Fong et al Iwatsuki et al 1986 1995 1996 1997 1999 607 434 1,568 280 1,001 305 33% 28% 27% 37% 32% - 40 33 42

Long term results – our data

Prognostic factors influencing long term results after curative surgery Extrahepatic disease; Primary tumor stage; Number and size of liver matastases; Disease free interval; Margins; Other ( age, CEA).

Prognostic factors for long term results- extrahepatic disease Mayo Clinic 0% 5 year survival with extrahepatic disease (22 patients); Memorial Sloan-Kettering Cancer Center Patients with and without extrahepatic disease 5 year survival 18% vs 38%;(1.001pts) Fong Y, Fortner J et al Ann Surg 230:309-318, 1999 Elias D, Lasser P, De/Cl/Nouveche, Dec, 1991 Registry of Hepatic Metastases Metastatic lymphadenopathy (portal and celiac nodes) markedly decreased survival with no 5 year survival reported (850 patients, retrospective study); Registry of Hepatic Metastases, Surgery, 103:278-288, 1988

Restrictions for surgery in case of extrahepatic disease Liver resection restricted in: Presence of metastasis in two or more organs - lung, liver, colon (recurence) in case of multiple metastasis in one of them Carcinomatosis, pleuritis, ascitis Presence of portal or celiac lymph node metastasis proved by biopsy and extra pathology?

Prognostic factors for long term results– primary tumor stage Patients with lymphatic spread have a decreased survival compared to patients without lymphatic spread, 41% vs 32% ( p = 0.05 analysis of 1.001 patients); Fong Y, Fortner J et al Ann Surg 230:309-318, 1999 Stage II primary have an improved outcome compared to patients with stage III primary; Scheele J., Stangl R. et al; World J Surg, 19:59-71,1995 Nordliger B., Guiget M et al; Cancer 77:1254-1262,1996

Suggestions for therapy in case of primary tumor spread Node positive patients – candidates for adjuvant therapy

Prognostic factors for long term results– number of liver metastases Increasing number of metastases – decreasing survival Experience- 155 patients who had 4 and more lesions: 5 – year survival after 9 to 20 metastases resected - 14%. increasing number of metastases and positive resection margin - independent prognostic factors (multivariate analysis). Weber SM, Jarnagin WR et al Ann Surg Oncol7:643-650, 2000 Statement- increased number of metastasis increasing likelihood of undetectable metastasis

Restrictions for surgery in case of multiple liver metastases 1- 3 metastasis in one liver lobe are suitable for curative liver resection Patients with 4 and more mts in one or both liver lobes are candidates for neoadjuvant treatment after 2 months chemotherapy in case of no manifestation of new metastasis possibilities of surgery should be discussed

Prognostic factors for long term results– disease free interval Experience- Difference of median survival in synchronous vs. metachronous disease 27 months vs. 37 months Scheele J., Stangl R. et al; World J Surg, 19:59-71,1995 Statements: Increasing disease-free interval associated with improved survival. Fong Y, Fortner J et al Ann Surg 230:309-318, 1999 Synchronous or early manifestation of liver metastases are poor prognostic factors

Suggestions after liver resection in case of short disease free interval Strong follow up protocol of resected patients with intent to detect new manifestation of metastasis Neoadjuvant, adjuvant chemotherapy

Prognostic factors for long term results– size of liver metastases Controversial opinions: Increasing tumor size – poor prognostic factor; Iwatsuki S, Dvorchik I et al, J Am Coll Surg 189 :291-299,1999 Tumor size – no influence on survival; Cady B, Jenkins RL et al Ann Surg 227:566-571, 1998 Clinical consideration (hypothesis): Large and solitary tumor because of long growing period should decrease likelihood of manifestation of new metastasis, Current consensus: There is no absolute metastasis size limit for surgical resection

Prognostic factors for long term results - margins Studies: Patients with positive resection margins ( noncurative) had a life expectancy similar to that of patients with unresectable disease; Steele G Jr, Bleday R et al J Clin Oncol 9:1105-112, 1991 Patients with minimally negative microscopic margins (1 to 9 mm) compared to patients with margins greater than 10 mm: 1. decreased 5-year survival; 34% vs 41% (p = 0.009) Scheele J., Stangl R. et al; World J Surg, 19:59-71,1995 23% vs 47% (p < 0.01) Registry of Hepatic Metastases, Surgery, 103:278-288, 1988 2. Increase in hepatic recurrence; Hughes KS et al Surgery 100:278-284, 1986

Obligations and Suggestions for surgeon in aspect of margins to resect with minimally clear margins > 10mm Suggestion- To try expand clear margins to 30mm

Poor prognostic factors As guidelines for patient selection Study Age Primary Tumor Stage No. of lesions Size Satellite lesions Bilobar Margins (<1cm) Disease Free Interval CEA Extra Hepatic disease Fong Iwatsuki Lise Cady Nordlinger Jamison Wanebo Scheele Doci + >1 >2 >3 >5 >8 <1yr <2,5yr <2yr

Actuality of surgical resection (I) Short term results

Short term results after liver resection morbidity - <25% mortality - <4% Study Mortality Morbidity Hepatobiliary compl. Infectious compl. Scheele et al Iwatsuki et al Nordlinger et al Cady et al Fong et al Doci et al Our data 4% 1% 2% 3% - 16% 8% 23% 24% 18% 21% 6% 7% 9%

Morbidity and Mortality after liver resection General complications: cardiovascular, pulmonary, etc. Infection, abscess; Hemorrhage. Specific complications: bile leak, biliary fistula, Liver failure ( can be decreesed < 5% with proper patient selection despite agresive surgical treatment).

Low morbidity and mortality depends on patient selection Preoperative evaluation: Medical condition similar to other major abdominal surgery ( particular attention to pulmonary and cardiac systems). 2. Preoperative Hepatic function;

Main contraindication for expanded liver resection Inability to preserve an adequate reserve of functional hepatic tissue;

Chance for survival after liver resection with normal liver function 70-75% of the liver can be resected without increasing the risk of postoperative liver failure in the absence of cirrhosis or fatty liver. Sasson A.R., Sigurdson E.R. et al; Seminars in Oncology; Vol 29, No 2, 2002

Patient selection – preoperative evaluation of Hepatic function Main question – extent of the operation? Clinical evaluation (Child – Pugh); Level of Bilirubinaemy; Indocianine green (ICG-5); CT volumetry.

Clinical evaluation (Child – Pugh) 1964m B C Albuminaemy (g/l) >35 30-35 <30 Bilirubinaemy (mkmol/l) <40 40-35 >50 Ascites No Easy control Hard control Encephalopathy I – II III – IV Nutrition Excelent Good Bad Operation risk Minimal Medium Big Postoperative mortality 0-5 % 10-15 % >25 % 1 year mortality 20-40 % 40-60 %

Liver resection volume guides No ascites or easy control Bilirubinaemy normal 18.8-25.6 μmol/l 27.4-32.5 μmol/l > 34.2 μmol/l Limited resection Enucleation Not resectable ICG-5 normal 10-19% 20-29% 30-39% > 40% Major surgery Bisegment- ectomy Segment- ectomy Limited resection Enucleation

CT volumetry of liver Liver sector Volume cm3 % Posterior 207.4 27.7 Anterior 149.9 19.7 Medial 163.3 21.5 Lateral 177.9 23.4 Caudal 22.7 2.9 Tumor 36.7 4.8

Preoperative procedures to increase volume of the liver Decreasing of blood supply to diseased part of the liver with intent to enlarge normal liver lobe: Portal vein embolisation Embolisation of hepatic artery

Intent to enlarge normal liver before surgery Transhepatic portal vein embolisation

Transileocolic portal vein embolisation scheme Intent to enlarge normal liver before surgery Transileocolic portal vein embolisation scheme RPV SMV Laparotomy and catheterisation of ileocolic vein